Ajanta Pharma has announced the establishment of a new subsidiary in Ireland, marking a significant step in the pharmaceutical company's international expansion strategy. The newly created entity will operate under the name Ajanta Pharma Ireland.

Strategic International Expansion

The formation of this Irish subsidiary represents Ajanta Pharma's continued focus on strengthening its global footprint. Ireland's strategic location within the European Union makes it an attractive destination for pharmaceutical companies seeking to establish operations that can serve the broader European market.

Corporate Structure Enhancement

The creation of Ajanta Pharma Ireland adds to the company's international subsidiary network, potentially providing enhanced operational flexibility and market access. This corporate structure expansion demonstrates the company's commitment to building a robust international presence across key pharmaceutical markets.

Market Positioning

By establishing operations in Ireland, Ajanta Pharma positions itself to better serve European markets while benefiting from Ireland's business-friendly regulatory environment. The subsidiary structure could facilitate improved distribution channels and regulatory compliance within the European pharmaceutical landscape.

This development reflects Ajanta Pharma's ongoing strategy to expand its international operations and strengthen its position in global pharmaceutical markets through strategic subsidiary formations.

Ajanta Pharma has announced its earnings conference call schedule for Q3FY26 results discussion, filing the notification under Regulation 30 of SEBI listing requirements on January 12, 2026. The pharmaceutical company will release its unaudited financial results for the third quarter of fiscal year 2026 followed by an investor interaction session.

Conference Call Details

The earnings conference call is scheduled for January 30, 2026, providing investors and analysts an opportunity to engage with the company's leadership team regarding financial performance and business developments.

Dial-in Access Options

The company has arranged multiple access methods to accommodate participants from different regions. A Diamond pass registration system offers faster connectivity for convenience.

Primary Access Numbers

• Universal Access: (+91 22 6280 1542) and (+91 22 7115 8372)
• Diamond pass registration available for expedited access

International Toll-Free Numbers

• USA: 18667462133
• UK: 08081011573
• Hong Kong: 800964448
• Singapore: 8001012045

Registration Process

Participants can register through the Diamond pass link to receive a calendar invite with passcode and PIN number. The access credentials will be activated 30 minutes before the scheduled conference time. The registration system includes step-by-step instructions for dialing in and reconnecting if disconnected.

Post-Call Availability

The earnings call playback will be accessible on the company's website at www.ajantapharma.com within 120 minutes after the session concludes. A complete transcript of the conference call will also be made available on the same platform.

Investor Relations Contacts

For queries related to the earnings call, investors can reach out to the designated investor relations team:

• Rajeev Agarwal: rajeev.agarwal@ajantapharma.com
• Abhineet Kumar: abhineet.kumar@ajantapharma.com

The announcement was signed by Gaurang Shah, Sr. VP – Legal & Company Secretary, ensuring compliance with regulatory disclosure requirements.